Skip to main content
. 2020 Sep 8;11:575072. doi: 10.3389/fmicb.2020.575072

FIGURE 1.

FIGURE 1

Influence of the gut microbiota on the effectiveness of immunotherapy. Anti-CTLA-4 and anti-PD-L1 therapies depend respectively on Bacteroides enrichment and Bifidobacterium abundance for their efficacy. T-cell activation and proliferation against tumor cells requires monoclonal antibodies that block the interaction between ligand and its respective receptor.